Limitations, Side Effects, and Importance of Blinding in Psilocybin Study

In a new study, psilocybin showed promise as a treatment for major depressive disorder (MDD). JAMA Associate Editor Donald C. Goff, MD, speaks with author Charles L. Raison, MD, from the Usona Institute, about the study, as well as Rachel Yehuda, PhD, Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies. Related Content:

• Single-Dose Psilocybin Treatment for Major Depressive Disorder
• Psychedelic Therapy—A New Paradigm of Care for Mental Health